ClinicalTrials.gg
CompletedNCT03279341Updated Sep 12, 2017

Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects

A Phase 4 interventional study of polyethylene glycol and Bisacodyl in Chronic Constipation, sponsored by University Hospital, Gasthuisberg. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by University Hospital, Gasthuisberg · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Dec 2012, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing Polyethylene Glycols in Constipation — 1 open to participants now, 1 under way, none of them phase 3. Polyethylene Glycols · Constipation.

Enrollment
10th of 10
10 · median 84
Started
2012
the only one that year
Phase 4
6 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
University Hospital, Gasthuisberg

Among the 10 studies testing Polyethylene Glycols in Constipation, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 4, and was the 7th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

1 of the 10 studies testing Polyethylene Glycols in Constipation is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Polyethylene Glycols

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Polyethylene Glycols in Constipation, or all of them as a file.
02

Study summary

This study aim was to evaluate the effect of pharmacological treatments normally used to treat functional constipation and in particular PEG, bisacodyl and prucalopride on colonic motility as assessed by high-resolution manometry.

Read the detailed description

Rationale: Several treatments with different modes of action are currently available for chronic constipation. This study will investigate the effect of these different modes of actions of PEG 3350 + electrolytes, bysacodyl and prucalopride and on colonic motility parameters (e.g. HAPC).

Objectives:Primary: to compare and determine the effects of PEG, bisacodyl and prucalopride on the number of colonic high amplitude propagated contractions (HAPCs) during a 12-hour intraluminal manometry in healthy subjects. Secondary: to evaluate the association between motility parameters and number and consistency of bowel movements in healthy subjects.

Investigational product, dose, and mode of administration: Regimen A: 13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution. Regimen B: 10 mg bisacodyl once daily oral administration with 125mL of water. Regimen C: 2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water.

Methodology: This is an open-label, randomized, reader-blinded, 3-period cross-over study investigating the effects of PEG 3350 + electrolytes, bisacodyl and prucalopride on colon motility with intraluminal manometry. On day 1 of each Treatment Period, a manometry catheter will be placed in the colon under conscious sedation and the colonic pressure will be continuously measured through 12 hours after administration of each of the investigational products (Regimen A, B or C).

Inclusion criteria: healthy male and non-pregnant, non-breastfeeding female participants, aged 18-65 years old at the time of consent. Exclusion criteria: use of medications within 48 h of dose initiation; structural or metabolic diseases that affect the gastrointestinal system and functional gastrointestinal disorders; previous abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, or hernia repair; known illnesses such as diabetes, cardiovascular or lung disease; use of agents that influence bowel habit, i.e. anticholinergics (not including antihistamines with anticholinergic properties), spasmolytics and prokinetics in the 7 days before the study.

03

Conditions studied

  • Chronic Constipation

Browse trials for

Keywords

  • laxatives
  • constipation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy male and non-pregnant, non-breastfeeding female participants, aged 18-65 years old at the time of consent

Exclusion criteria

Exclusion Criteria:

  • use of medications within 48 h of dose initiation; structural or metabolic diseases that affect the gastrointestinal system and functional gastrointestinal disorders; previous abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, or hernia repair; known illnesses such as diabetes, cardiovascular or lung disease; use of agents that influence bowel habit, i.e. anticholinergics (not including antihistamines with anticholinergic properties), spasmolytics and prokinetics in the 7 days before the study
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    polyethylene glycol, osmotic laxitive

    13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution

    Drug: polyethylene glycol

  • Active comparator
    bisacodyl, stimulant laxative

    10 mg bisacodyl once daily oral administration with 125mL of water

    Drug: Bisacodyl

  • Active comparator
    prucalopride, prokinetic

    2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water

    Drug: Prucalopride

Interventions

06

What researchers measure

Primary outcomes

  1. colonic motor patterns during PEG, bisacodyl and prucalopride in healthy subjects.

    number of colonic high amplitude propagated contractions (HAPCs)

    Time frame: during a 12-hour intraluminal manometry

Secondary outcomes

  1. association between motility parameters and number and consistency of bowel movements in healthy subjects

    number of colonic motor patterns and number of bowel movements and stool consistency assessed by Bristol Stool Chart

    Time frame: during a 12-hour intraluminal manometry

07

Study locations

1 site
  • TARGID
    Leuven, 3000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Mar 2016, 39 months.

Of 34 phase 4 interventional studies under Constipation, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Sep 12, 2017
StartActual
Dec 3, 2012
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Sep 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03279341
Lead sponsor
University Hospital, Gasthuisberg
Responsible party
Maura Corsetti (Associate Professor of Gastroenterology, University Hospital, Gasthuisberg) — Principal investigator
First posted
Sep 12, 2017
Start date
Dec 3, 2012
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Sep 12, 2017

Study contacts

Jan Tack, MD. PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polyethylene Glycols · Bisacodyl · Prucalopride

Start the discussion